Drug intelligence / Profile preview

amphotericin B + isavuconazole

Development stage: Preclinical
Lead developer: Basilea Pharmaceutica
Modality: Small Molecules
Administration: Intravenous, Oral

Overview

A combination antifungal therapy consisting of amphotericin B (a polyene antifungal) and isavuconazole (a triazole antifungal). This combination has demonstrated synergistic effects against various fungal pathogens, particularly Mucorales species that cause mucormycosis. In experimental models, the combination showed superior efficacy compared to either drug alone, with higher survival rates and greater reduction in fungal burden. The combination may be particularly valuable for treating severe, disseminated, or refractory fungal infections.

Targets

CYP51A1 (Sterol 14α-demethylase)Ergosterol

Beyond the preview

Go deeper on amphotericin B + isavuconazole.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on amphotericin B + isavuconazole.

Explore the full profile